M&A Deal Summary |
|
---|---|
Date | 2023-06-21 |
Target | Ellab |
Sector | Medical Products |
Buyer(s) | Novo Holdings A/S |
Sellers(s) | EQT |
Deal Type | Secondary Buyout |
SEARCH BY
Try For Free 7-Day Free Trial
Novo Holdings A/S is a Danish holding company and the investment arm of the Novo Nordisk Foundation. Novo Holdings' objective is to grow the assets of the Foundation and improve the lives of people around the world. In addition to investing in equity and fixed income securities, Novo Holdings pursues direct investments in life science companies. Novo Holdings A/S was established in 1999 and is headquartered in Hellerup, Denmark.
DEAL STATS | # |
---|---|
Overall | 11 of 12 |
Sector (Medical Products) | 2 of 2 |
Type (Secondary Buyout) | 8 of 8 |
Country (Denmark) | 3 of 3 |
Year (2023) | 2 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-06-06 |
Paratek Pharmaceuticals
Boston, Massachusetts, United States Paratek Pharmaceuticals is a bio-pharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek Pharmaceuticals was founded in 1996 and is based in Boston, Massachusetts. |
Buy | $462M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2024-02-05 |
Catalent
Somerset, New Jersey, United States Catalent is a provider of solutions for drugs, biologics and consumer health products. Among its core offerings, it develops and manufactures oral and sterile medication in nearly all dosage forms, holds patents for softgel (e.g. “Liqui-Caps” and “Vegicaps”) and Zydis fast-dissolve technologies used in many popular prescription and over-the-counter medicine. Catalent was founded in 2007 and is based in Somerset, New Jersey. |
Buy | $16.5B |
Category | Private Equity Firm |
---|---|
Founded | 1994 |
PE ASSETS | 50.0B EUR |
Size | Mega |
Type | Sector Agnostic |
EQT is a global private equity group that purses a variety of investment strategies around the world. EQT is divided into several investment disciplines, including private capital, real assets, credit, and venture. The Firm's private capital group targets large, market-leading enterprises (investment size of €125 to €1.5 billion) across Europe and the US, as well as mid-market, growth companies (investment size of €40 to €125 million) across the US, Europe, China, and Southeast Asia. The Firm's real assets group seeks to identify control or co-control equity investments (investment size of €500 to €1 billion) in medium-sized infrastructure companies that provide an essential service to society, are recession resilient, and have secure cash flows. EQT's credit group provides flexible, long-term debt capital solutions to medium-sized European businesses, across a wide range of sectors. EQT was established in 1994 and is headquartered in Stockholm, Sweden.
DEAL STATS | # |
---|---|
Overall | 170 of 175 |
Sector (Medical Products) | 10 of 12 |
Type (Secondary Buyout) | 52 of 55 |
Country (Denmark) | 20 of 20 |
Year (2023) | 4 of 7 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-06-20 |
HDFC Credila
Mumbai, India HDFC Credila is an education loan company, supporting tens of thousands of Indian students every year with tailored financing solutions for undergraduate and postgraduate studies. HDFC Credila is based in Mumbai, India. |
Buy | Rs10.0B |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-07-20 |
Dechra Pharmaceuticals
Northwich, United Kingdom Dechra Pharmaceuticals is an international specialist in veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacturing, sales, and marketing of quality products exclusively for veterinarians worldwide. The company's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. Dechra Pharmaceuticals was founded in 1998 and is based in Northwich, United Kingdom. |
Buy | £4.5B |